In Vitro Diagnostics (IVD) News: Breaking In Vitro Diagnostics (IVD) News, Comments and Articles. - Page: 5

02:22 EDT 25th October 2014 | BioPortfolio

In Vitro Diagnostics (IVD) News - Page: 5Twitter RSS

Read the latest In Vitro Diagnostics (IVD) News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on In Vitro Diagnostics (IVD).

Search or Follow Our In Vitro Diagnostics (IVD) - Page: 5 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More In Vitro Diagnostics (IVD) - Page: 5 News.
You can also follow our In Vitro Diagnostics (IVD) - Page: 5 news stories on Twitter: @IVDiagnostics

Showing "invitro diagnostics vitro" News Articles 101 to 125 of 3,900+

Tuesday 21st October 2014

New Innovations Advance Upstream and Downstream Bioprocessing for Biopharmaceutical Manufacturers

New single-use fermentor, cell culture media and purification technologies increase performance, productivity and efficiency New technology innovations in single-use, cell culture and purification are now available to address the evolving requirements of biologic drug discovery and production for global biopharma manufacturers. These solutions will be ...

Aptose Biosciences Announces Approval For Listing On The Capital Market Shares To Begin Trading Under The Symbol APTO

SAN DIEGO and TORONTO, Oct. 21, 2014 /PRNewswire/ - Aptose Biosciences Inc. (Aptose) (TSX:APS), a clinical-stage company developing targeted agents and molecular diagnostics to treat the underlying mechanisms of cancer, announced today that its common shares...

Orion Group Interim Report January-September 2014

ORION CORPORATION / INTERIM REPORT / JANUARY-SEPTEMBER 2014 / 21 October 2014 at 12:00 noon EEST Orion Group Interim Report January-September 2014 Orion's net sales in January-September 2014 totalled EUR 760 million (EUR 734 million in January-September 2013). Operating profit was EUR 217 (202) million. Profit before taxes was EUR 214 (200) million. Equity ratio w...

One Call Care Management Shares Workers’ Compensation Dental Expertise with Occupational Health Professionals

Laura Gorman, RN, Outlines Best Practices for Dental Claims Management Dental injuries that occur on the job are challenging, complicated, and costly for workers’ compensation programs, according to Laura Gorman, RN and Vice President of Clinical Sales at One Call Dental + Doctor (One Call). Gorman presen

Exalenz Bioscience Launches Pivotal Study of World’s First Breath-Based Test to Diagnose Clinically Significant Portal Hypertension

Portal hypertension is the most common complication of cirrhosis, accounting for significant morbidity and mortality Multinational study to be conducted in Europe and the U.S. Exalenz Bioscience (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver dis...

Cancer Research Technology introduces Ximbio, an Online Reagents Portal.

Ximbio aims to change the way reagents are searched, sourced and shared London, UK, 20 October 2014: Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK, announced today the launch of Ximbio (MailScanner has detected a possible fraud attempt from "mailtrack.me" claiming to be www.ximb.io), an online reagents portal for the life science...

'Designer' nanodevice could improve treatment options for cancer sufferers

Cancer diagnostics and treatment options could be drastically improved with the creation of a ‘designer’ nanodevice currently being developed by an international team of researchers. The diagnostic 'nanodecoder', which will consist of self-assemb...

Arizona Company Launches Lung Cancer Test For $99

PHOENIX, Oct. 21, 2014 /PRNewswire/ -- Global Cancer Diagnostics Inc. today announced the availability of The Lung Cancer Test™ beginning, October 20, 2014.  All required Clinical Validation studies are complete with excellent results. The Test detects the presence of the required biomarkers that aid in the early detection of lung cancer. Global Cancer Diagnostics (GCDx) plans to o...

Aptose Biosciences Announces Approval for Listing on the NASDAQ Capital Market Shares to Begin Trading Under the Symbol APTO

SAN DIEGO and TORONTO, Oct. 21, 2014 /PRNewswire/ - Aptose Biosciences Inc. (Aptose) (TSX:APS), a clinical-stage company developing targeted agents and molecular diagnostics to treat the underlying mechanisms of cancer, announced today that its common shares have been approved for listing on the NASDAQ Capital Market under the symbol "APTO". Aptose will begin trading on NASDAQ on or around ...

Alere Inc. Schedules Conference Call for 8:30 a.m. ET October 28, 2014 to Discuss Third Quarter 2014 Results

WALTHAM, Mass., Oct. 21, 2014 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced that it will release its third quarter 2014 earnings on Tuesday, October 28, 2014. The Company will also host a conference call beginning at 8:30 a.m. (Eastern Time) on that date to discuss these results and other corporate matters. During the conference call, the Compan...

Device/Diagnostics Quarterly Deal Statistics, Q2 2014

Device funding increased 123% to $1.6 billion in Q2, and M&A activity was overshadowed by Medtronic’s massive $47 billion acquisition of Covidien. Diagnostics fundraising dropped slightly to $522 million, and there were multiple takeovers of li...

Abaxis Announces Distribution Agreement with Henry Schein Animal Health

UNION CITY, Calif., Oct. 21, 2014 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care instruments and consumables for the medical, research, and veterinary markets worldwide and providing reference lab services to the veterinary and research markets in the United States, announced today it has entered into a definitive non-exclusive distributi...

Henry Schein Animal Health Announces Strategic Relationship With Abaxis To Bring Diagnostic Products To U.S. Veterinary Practices

MELVILLE, N.Y., Oct. 21, 2014 /PRNewswire/ -- Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, announced today that Henry Schein Animal Health has entered into a strategic relationship with Abaxis, Inc. (NASDAQ: ABAX), a manufacturer of point-of-care instruments and consumables for ...

Hatchtech Announces Successful Results from Phase 2 Ovicidal Study

Ovicidal efficacy confirmed in a Phase 2 clinical study Primary endpoint met with 100% of eggs treated with Xeglyze™ Lotion remaining unhatched following a single 10 minute application Results confirm previous in-vitro studies, where no eggs hatched following treatment with Xeglyze™ Lotion Clini...

Monday 20th October 2014

AAV2-mediated follistatin overexpression induces ovine primary myoblasts proliferation

Background: Follistatin (FST) has been shown to bind to some TGF-? family members and can function as a potent myostatin (MSTN) antagonist. Recent studies have revealed that over-expression of FST by adeno-associated viruses increases muscle growth i...

Multicenter Study Reinforces the Clinical Benefit of the WATS3D Biopsy for Detection of Barrett's Esophagus and Dysplasia

SUFFERN, NY -- (Marketwired) -- 10/21/14 -- CDx Diagnostics announced today that the WATS3D biopsy markedly increased detection of esophageal precancer in a new study of 1655 patients. Adding WATS3D to standard forceps biopsy testing of the esophagus produced an added yield of more than 100% for both Barrett's esophagus and dysplasia. The results are being presented at the American College of Gas...

Rosetta Genomics and the Institute of Molecular Translational Medicine Partner on Development of Thyroid Cancer Diagnostic

PRINCETON, NJ and REHOVOT, ISRAEL and OLOMOUC, CZECH REPUBLIC -- (Marketwired) -- 10/21/14 -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the initiation by the European Infrastructure for Translational Medicine (EATRIS), of a new public-private translational research project between Rosetta Genomics and the Institute of...

Critical Outcome Technologies and MD Anderson Cancer Center to Evaluate COTI-2 in Treating Head and Neck Cancers

LONDON, ONTARIO -- (Marketwired) -- 10/21/14 -- Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced today that it recently executed a material transfer agreement ("MTA") with Dr. Jeffery Myers, MD, PhD, FACS of The University of Texas MD Anderson Cancer Center for the continued evalua...

$7.9B Molecular Diagnostics Market Analysis and Global Review

DALLAS, Oct. 21, 2014 (GLOBE NEWSWIRE) -- Global molecular diagnostics market will reach $7,956.9 million by 2018, growing at a CAGR of 9.7% during the forecast period (2013–2018) according this 2014 research report on the worldwide molecular diagnostics industry. The driving forces of the molecular diagnostics market include the rising incidences of infectious diseases, genetic disorders, canc...

Exact Sciences to Host Third-Quarter 2014 Results Webcast and Call

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call to discuss its third-quarter 2014 financial results on Oct. 27, 2014. Third-Quarter 2014 Webcast and Conference Call Details     Date: ...

HealthCare Royalty Partners closes $1.5B fund

HealthCare Royalty Partners closed its third fund, HealthCare Royalty Partners III, at $1.5 billion, which the firm said exceeded its original target by over 75%. Managing Partner Todd David told BioCentury the firm had targeted $850 million. Inves...

Emerging Markets Earnings Roundup: Roche (Part 2)

Roche feels the heat still from Tarceva competition in China, but Japan regains luster as sales tax hit dims and diagnostics benefit as governments in emerging markets ramp up health care spending.

Agilent Technologies Introduces Focused Exome Kit with Unparalleled Coverage, Speed, Flexibility for Disease Research

Solution Ideal for Both High-Throughput and Benchtop Next-Generation Sequencing Applications Agilent Technologies Inc. (NYSE: A) today introduced the SureSelect Focused Exome, a target enrichment solution that enables deep coverage of only those target regions that have been associated with disease. The latest design

The Broe Group Invests in $120 Million Round of Funding for Invitae, a Healthcare Technology Company Creating a Genetic Information Business

Three Leaf Ventures, a wholly-owned subsidiary of The Broe Group established to invest in cutting-edge technology in healthcare, participated in a recently-announced $120 million round of funding for Invitae, a San Francisco-based genetic information company. Invitae’s mission is to bring genetic information into routine medical practice to improve the q...

25 Testing Innovations Critical to IVD Market Growth

New test innovations will be the source of revenue growth in the in vitro diagnostic (IVD) test industry, especially as companies struggle with reimbursement challenges, according to Kalorama Information.Read more about 25 Testing Innovations Critica...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks